UC Davis Health Clinical Studies

A Study of Experimetnal VarIthena on Wound Healing in Venous Leg Ulcers (VLU)

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

The purpose of this registry is to look at how experimental Varithena® injectable foam works. It will be given to patients who have chronic venous insufficiency (commonly known as “varicose veins”) with leg wounds. The decision to provide you with such medication has been left up to your treating physician and is not being driven by or impacted by this study. The purpose of this project is to collect data about your leg wounds. We hope to learn the impact of treatment on the rate of healing, the rate of repeated wounds, as well as the impacts to your level of pain and quality of life.

Drug study
Any, age 18 years or older

Safety and Dose Study of an Experimental Viral Vector Used for Gene Transfer in Hemophilia A Participants

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

This study will test a study drug called experimental BAX 888. It is known as a gene transfer product for people with severe hemophilia A. This is a first-in-human clinical research study, which means BAX 888 has not been tested in human subjects before. The use of BAX 888 in this research study is investigational. This means that BAX 888 has not been approved by the FDA to treat hemophilia A. There is currently not enough information to know how well BAX 888 works to treat conditions like hemophilia A. This will be examined in this clinical research study. The main goals of this study are: • To investigate the safety of BAX 888 when it is given as a single infusion (a slow injection into a vein) to subjects with hemophilia A. • To investigate the optimum amount of BAX 888 necessary for the human body to produce enough Factor 8. • To look at how BAX 888 affects your immune system and the activity of clotting Factor 8 in your blood. • To answer scientific questions about gene transfer for hemophilia A.

Drug study, Phase [/1/,/ /2/]
Male, age 18 to 75 years old

A Study of Experimental ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma (liver cancer)

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

The purpose of this study is to find out if Study Drug ET140202 T cells are safe and if there are beneficial effects in people with liver cancer. The investigational study drug is ET140202 T cells. The word “investigational” means the study drug is still being tested in research studies and is not approved by the FDA. Your ET140202 T cell product will be made from your own T cells, a specific type of white blood cell. Your T cells will be genetically-modified in the laboratory. This means the T cells are changed by inserting additional pieces of DNA (genetic material) into the cells. This makes them recognize and kill liver cancer cells. The process of making your ET140202 T cell product is described here: • Your cells will be collected by a procedure called leukapheresis. This involves collecting your blood and separating your white blood cells from other blood components. • Your T cells, a specific type of white blood cell, will be isolated and grown in the laboratory. • Your T cells will be treated with a vector. Vectors are type of virus that can enter cells and can change the way the cell acts. • After adding the new ET140202-specific genetic material, your ET140202 T cells will be grown to larger numbers. Afterwards, the cells are washed to select the best cells and frozen. • Your ET140202 T cells will be tested to make sure they are safe for use and then administered to you.

Biological study, Phase [/1/,/ /2/]
Any, age 18 years or older

A Study of Engineered Donor Grafts (TregGraft) for Allogeneic Transplantation for Hematologic Malignancies (blood cancer)

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

You are being asked to take part in a research study of a type of blood stem cell transplant called TregGraft. TregGraft is being tested as a possible treatment of blood cancers and conditions highly likely to turn into blood cancer. TregGraft is an experimental therapy, meaning that it is not approved by the FDA. TregGraft is the study treatment in this research study. You will not receive TregGraft. Rather, it is the blood cell transplant that will be given to the recipient and will be made from your blood cells. A key part of TregGraft are healthy blood-forming cells. These will be isolated from your blood cells. When placed in the recipient’s bloodstream, they will grow and make new healthy red blood cells, white blood cells, and platelets. TregGraft also includes other specific white blood cell populations including regulatory T cells. These will also be isolated from your blood cells. When given to transplant recipients, they may prevent some of the known complications of blood cell transplants. One example is graft-versus-host disease (GVHD), a condition that involves the immune attack on recipient tissues by donor cells. TregGraft also includes “conventional” T cells, that may help fight infection or cancer, but also carry a risk of causing GVHD.

Biological study, Phase 1
Any, age 18 to 65 years old

Study on Experimental Olaparib Plus Abiraterone for Metastatic Castration-resistant Prostate Cancer

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

This research study is for patients who have metastatic Castration-resistant Prostate Cancer (mCRPC). The reason for the study is to find a more effective treatment for this disease. The research team hopes to find out if an experimental medication called olaparib is safe and effective. It will be tested in patients who are also given abiraterone treatment. Olaparib (tradename Lynparza™) is approved by the FDA for other types of cancer. It is considered experimental in this study. Abiraterone is already an approved medication for the treatment of some patients with prostate cancer.

Drug study, Phase 3
Male, age 18 to 99 years old

A Study of Experimental Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Eczema)

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

This study will test the effectiveness and safety of the experimental study drug upadacitinib (ABT-494). It will be compared to a placebo, which is an inactive substance that looks like the study drug. Experimental ABT-494 is being tested for the treatment of moderate to severe atopic dermatitis (AD). The study drug is an oral medication (taken by mouth) that is a tablet taken once a day. An experimental drug is one that has not been approved by the FDA.

Drug study, Phase 3
Any, age 12 to 75 years old

A Study of Experimental Elacestrant vs. Standard of Care for ER+/HER2- Advanced Breast Cancer

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

You are being asked to take part in this research study because you have advanced breast cancer that is either: - estrogen receptor positive (ER+) or - human epidermal growth factor negative (HER2-) Researchers want to find out if an experimental drug called elacestrant, can help people with your type of advanced breast cancer. Elacestrant is also known as RAD1901. It is an experimental drug that impacts the estrogen receptor. It is under investigation for the treatment of ER+, HER2- advanced breast cancer. An “experimental drug” is a drug that is being tested and is not approved for sale by the FDA. Researchers want to test elacestrant in subjects with advanced breast cancer. They hope to learn: - if it can prolong time to worsening (progression) of the breast cancer, - how it affects cancer cells and - about any unwanted health effects, also called “side effects”, it may cause.

Drug study, Phase 3
Any, age 18 years or older

A Study of the Safety and Activity of Experimental GS-6207 Injection for HIV-1 Infected Adults

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

The purpose of this study is to test the experimental medicine GS-6207 (referred to as study drug). We hope to determine how it affects the HIV infection in your body and how long the study drug stays in your body. The safety and how well the study drug is tolerated will also be determined by using: - physical exams, - laboratory tests, and - any symptoms or problems you might experience during the study.

Drug study, Phase 1
Any, age 18 to 65 years old

A Study of Experimental NGM120 Combination Therapy for Advanced Solid Tumors and Pancreatic Cancer

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

NGM120 is an experimental drug made by NGM Biopharmaceuticals, Inc. (the “Sponsor” of this clinical trial). The term “experimental” means that the drug has not been approved by the U.S. Food and Drug Administration (FDA). NGM120, given as an injection, is designed to block a factor that is associated with cancer. NGM120 has shown in various animal models of cancer to reduce tumor size and improve symptoms of cancer. The purpose of this study is to find out the effects of the study drug “NGM120.” We wil also test the combination of NGM120 and standard therapy (gemcitabine and Abraxane). We want to know the effect it may have on you and your type of cancer and your cancer associated loss of appetite, weight loss and loss of muscle.

Biological study, Phase 1
Any, age 18 years or older
Loading